Axsome Therapeutics is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of central nervous system (CNS) disorders
The company’s research is centered on addressing some of the most challenging conditions in mental health and neurological disorders, including depression, migraine, and Alzheimer’s disease. Axsome is dedicated to advancing its pipeline of drug candidates through rigorous clinical trials with the goal of providing new and effective treatment options to patients and improving their quality of life. Through its commitment to science and patient care, Axsome aims to make significant contributions to the field of CNS therapeutics.
Needham initiated coverage on Axsome Therapeutics, highlighting its diverse CNS portfolio. The analyst predicts an 8-10x risk-adjusted topline growth in five years, driven by marketed drugs Auvelity and Sunosi, along with promising late-stage assets.
